Market Overview

UPDATE: Tigress Initiates Coverage On Illumina

Share:
Related ILMN
What's The Single Best $10,000 Investment To Hold For The Next 25 Years?
Short Interest Surges In Illumina And Vertex Pharmaceuticals

In a report released Friday, Tigress analyst Philip Van Deusen initiated coverage on Illumina (NASDAQ: ILMN) with a Buy rating.

Analysts at Tigress favor Illumina for reducing costs in its genomic health progress with its genetic testing, diagnosis and individualized treatment. Illumina's development of hardware will strengthen, influencing an increase to barriers to entry. Tigress holds high expectations for Illumina sequencing machines, growing 51 percent year over year and making a majority of the company's revenue.

Latest Ratings for ILMN

DateFirmActionFromTo
Jun 2016CL KingInitiates Coverage onBuy
May 2016CitigroupMaintainsBuy
May 2016Morgan StanleyMaintainsEqual-weight

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: Philip Van Deusen TigressInitiation Analyst Ratings

 

Related Articles (ILMN)

View Comments and Join the Discussion!